
Manuel Hernandez-Guerra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4061279/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hepatitis C diagnosis slowdown in high-prevalence groups and using decentralised diagnostic strategies during the COVID-19 pandemic. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.1	2
2	Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes. Gut, 2022, 71, 2138-2140.	6.1	9
3	Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study. Alimentary Pharmacology and Therapeutics, 2022, 56, 131-143.	1.9	9
4	Transcriptional response of aldosterone target genes in the rat and human distal colon during hepatic cirrhosis. FASEB Journal, 2022, 36, .	0.2	0
5	Appropriateness of high-priority criteria and safety of endoscopy procedures during the COVID-19 lockdown. PLoS ONE, 2022, 17, e0267112.	1.1	0
6	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. Gastroenterology, 2021, 160, 193-205.e10.	0.6	97
7	Hepatitis C virus media coverage favorably impacts on antibody testing in the non-interferon era. Journal of Public Health, 2021, 43, 385-391.	1.0	4
8	Increasing the low residue diet to 3 days does not improve the bowel cleansing in hard to prepare patients: Post hoc analysis of a randomized controlled trial. GastroenterologÃa Y HepatologÃa (English Edition), 2021, 44, 183-190.	0.0	0
9	An Enhanced High-Volume Preparation for Colonoscopy Is Not Better Than a Conventional Low-Volume One in Patients at Risk of Poor Bowel Cleansing: A Randomized Controlled Trial. Frontiers in Medicine, 2021, 8, 654847.	1.2	2
10	Increasing the low residue diet to 3 days does not improve the bowel cleansing in hard to prepare patients: Post hoc analysis of a randomized controlled trial. GastroenterologÃa Y HepatologÃa, 2021, 44, 183-190.	0.2	2
11	Carotid Plaque Assessment Reclassifies Patients with Inflammatory Bowel Disease into Very-High Cardiovascular Risk. Journal of Clinical Medicine, 2021, 10, 1671.	1.0	8
12	Usefulness of prioritization systems during the resumption of gastrointestinal endoscopy activity during the COVID-19 pandemic. Endoscopy, 2021, 53, 662-663.	1.0	2
13	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsyâ€proven nonalcoholic fatty liver disease subjects. Liver International, 2021, 41, 2076-2086.	1.9	13
14	El paciente tratado de hepatitis C como fuente potencial de derivación de nuevos casos. GastroenterologÃa Y HepatologÃa, 2021, 44, 704-710.	0.2	0
15	Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study. American Journal of Gastroenterology, 2021, 116, 2250-2257.	0.2	14
16	Endometriosis polipoide simulando una neoplasia avanzada de ovario con infiltración de la pared intestinal: descripción ecoendoscópica del caso. GastroenterologÃa Y HepatologÃa, 2021, 44, 433-434.	0.2	0
17	Insulin Resistance Is Not Increased in Inflammatory Bowel Disease Patients but Is Related to Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2021, 10, 3062.	1.0	6
18	Telemedicine and decentralized hepatitis C treatment as a strategy to enhance retention in care among people attending drug treatment centres. International Journal of Drug Policy, 2021, 94, 103235.	1.6	10

#	Article	IF	CITATIONS
19	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. Journal of Hepatology, 2021, 75, 342-350.	1.8	28
20	QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease. Journal of Clinical Medicine, 2021, 10, 4102.	1.0	1
21	Hepatitis C-treated patients as a potential source for referral of new cases. GastroenterologÃa Y HepatologÃa (English Edition), 2021, 44, 704-704.	0.0	Ο
22	Prediction of liver stiffness by serum indexes in HCV-infected patients with or without HIV coinfection. Medicine (United States), 2021, 100, e27838.	0.4	2
23	Estimated glomerular filtration rate by formulas in patients with cirrhosis: An unreliable procedure. Liver International, 2021, , .	1.9	3
24	Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. Scientific Reports, 2021, 11, 24133.	1.6	13
25	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Research, 2020, 174, 104694.	1.9	39
26	Patients with suboptimal hepatitis B virus diagnostic characterization are at risk of liver fibrosis progression. European Journal of Gastroenterology and Hepatology, 2020, 32, 426-432.	0.8	1
27	Electronic Alerts as a Simple Method for Amplifying the Yield of Hepatitis C Virus Infection Screening and Diagnosis. American Journal of Gastroenterology, 2020, 115, 9-12.	0.2	12
28	International and multicenter realâ€world study of sorafenibâ€ŧreated patients with hepatocellular carcinoma under dialysis. Liver International, 2020, 40, 1467-1476.	1.9	15
29	Risk of liver fibrosis progression in patients with suboptimal diagnosis of hepatitis C virus infection. European Journal of Gastroenterology and Hepatology, 2020, 32, 528-534.	0.8	5
30	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. Journal of Hepatology, 2020, 73, 1082-1091.	1.8	112
31	Evaluación de la precisión diagnóstica del sistema Cobas 6800 para la detección de los niveles de viremia del virus de la hepatitis C a partir de muestras de gotas de sangre seca en papel de filtro. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 267-274.	0.3	6
32	Pre-Procedural Antibody Testing for SARS-CoV-2 in routine endoscopic practice. Revista Espanola De Enfermedades Digestivas, 2020, 113, 116-118.	0.1	6
33	Sexual behaviour and poor hygiene are related to recent hepatitis a virus community outbreaks. Revista Espanola De Enfermedades Digestivas, 2020, 112, 448-455.	0.1	4
34	Preemptiveâ€TIPS Improves Outcome in Highâ€Risk Variceal Bleeding: An Observational Study. Hepatology, 2019, 69, 282-293.	3.6	144
35	Chronic kidney disease staging with cystatin C or creatinine-based formulas: flipping the coin. Nephrology Dialysis Transplantation, 2019, 34, 287-294.	0.4	22
36	Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain. PLoS ONE, 2019, 14, e0225061.	1.1	4

#	Article	IF	CITATIONS
37	Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. Journal of Hepatology, 2019, 71, 666-672.	1.8	67
38	Predictive factors for not undergoing RNA testing in patients found to have hepatitis C serology and impact of an automatic alert. Journal of Viral Hepatitis, 2019, 26, 1117-1123.	1.0	19
39	Impact of a 1-day versus 3-day low-residue diet on bowel cleansing quality before colonoscopy: a randomized controlled trial. Endoscopy, 2019, 51, 628-636.	1.0	40
40	Gap junctions in liver disease: Implications for pathogenesis and therapy. Journal of Hepatology, 2019, 70, 759-772.	1.8	30
41	Eliminación de la hepatitis C. Documento de posicionamiento de la Asociación Española para el Estudio del HÃgado (AEEH). GastroenterologÃa Y HepatologÃa, 2019, 42, 579-592.	0.2	25
42	Enfermedad hepática por alcohol. GuÃas de práctica clÃnica. Documento de consenso auspiciado por la AEEH. GastroenterologÃa Y HepatologÃa, 2019, 42, 657-676.	0.2	12
43	Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD). Revista Espanola De Enfermedades Digestivas, 2019, 111, 264-269.	0.1	16
44	Documento de consenso. Manejo de la enfermedad hepÃ _i tica grasa no alcohólica (EHGNA). GuÃa de práctica clÃnica. GastroenterologÃa Y HepatologÃa, 2018, 41, 328-349.	0.2	71
45	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. Hepatology, 2018, 67, 612-622.	3.6	55
46	Risk factors for inadequate bowel preparation: a validated predictive score. Endoscopy, 2017, 49, 536-543.	1.0	51
47	Comparison of Two Intensive Bowel Cleansing Regimens in Patients With Previous Poor Bowel Preparation: A Randomized Controlled Study. American Journal of Gastroenterology, 2017, 112, 951-958.	0.2	51
48	Effect of season and sunlight on viral kinetics during hepatitis C virus therapy. BMJ Open Gastroenterology, 2017, 4, e000115.	1.1	6
49	Risk of Advanced Neoplasia in First-Degree Relatives with Colorectal Cancer: A Large Multicenter Cross-Sectional Study. PLoS Medicine, 2016, 13, e1002008.	3.9	20
50	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. Journal of Hepatology, 2016, 65, 532-542.	1.8	115
51	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology, 2016, 150, 1160-1170.e3.	0.6	232
52	Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening. Digestive and Liver Disease, 2016, 48, 542-551.	0.4	23
53	Contribution of Cyclooxygenase End Products and Oxidative Stress to Intrahepatic Endothelial Dysfunction in Early Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0156650.	1.1	37
54	Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival. United European Gastroenterology Journal, 2015, 3, 284-293.	1.6	4

#	Article	IF	CITATIONS
55	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. Annals of Hepatology, 2015, 14, 477-86.	0.6	0
56	Role of gap junctions modulating hepatic vascular tone in cirrhosis. Liver International, 2014, 34, 859-868.	1.9	22
57	Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests. Clinical Gastroenterology and Hepatology, 2014, 12, 1708-1716.e4.	2.4	13
58	Equivalency of Fecal Immunochemical Tests and Colonoscopy in Familial Colorectal Cancer Screening. Gastroenterology, 2014, 147, 1021-1030.e1.	0.6	52
59	Chronic intermittent hypoxia aggravates intrahepatic endothelial dysfunction in cirrhotic rats. Hepatology, 2013, 57, 1564-1574.	3.6	21
60	Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology, 2013, 58, 2079-2088.	3.6	48
61	Immunogenicity and Acceptance of Influenza A (H1N1) Vaccine in a Cohort of Chronic Hepatitis C Patients Receiving Pegylated-Interferon Treatment. PLoS ONE, 2012, 7, e48610.	1.1	2
62	Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood, 2010, 115, 388-395.	0.6	43
63	Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. Journal of Gastroenterology, 2010, 45, 703-712.	2.3	105
64	Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow-up study. Hepatology, 2010, 51, 210-218.	3.6	458
65	Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study. European Journal of Gastroenterology and Hepatology, 2009, 21, 1062-1067.	0.8	15
66	Etiology, Management, and Outcome of the Budd-Chiari Syndrome. Annals of Internal Medicine, 2009, 151, 167.	2.0	422
67	Extrahepatic Portal Vein Thrombosis. Seminars in Liver Disease, 2008, 28, 282-292.	1.8	115
68	Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis. American Journal of Gastroenterology, 2006, 101, 506-512.	0.2	228
69	Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. Hepatology, 2006, 43, 27-33.	3.6	39
70	Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. Hepatology, 2006, 43, 34-41.	3.6	31
71	Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology, 2006, 43, 485-491.	3.6	106
72	Increased Hepatic Resistance. Journal of Clinical Gastroenterology, 2005, 39, S131-S137.	1.1	55

#	Article	IF	CITATIONS
73	Portal Hypertension Secondary to Myelofibrosis: A Study of Three Cases. American Journal of Gastroenterology, 2005, 100, 2355-2358.	0.2	30
74	PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology, 2004, 40, 1197-1202.	3.6	142
75	Are there Predictive Factors of Severe Liver Fibrosis in Morbidly Obese Patients with Non-alcoholic Steatohepatitis?. Obesity Surgery, 2001, 11, 254-257.	1.1	80
76	Gene expression of tumor necrosis factor [alpha] and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology, 2001, 34, 1158-1163.	3.6	572